Description
ADCC-enhanced Taplitumomab paptox is a non-fucosylated anti-CD19 therapeutic biobetter antibody.
Antibody Indication
Cancers
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 Molecule
Background
CD19 (CD19 Molecule) is a Protein Coding gene.
Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.
Among its related pathways are RET signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers.
Gene Ontology (GO) annotations related to this gene include signal transducer activity, downstream of receptor.
Alternative Names
CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;
Gene ID
930
UniProt ID
P15391
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.
Related Pathways
Its related pathways are RET signaling and B cell receptor signaling pathway (KEGG).
Function
As a co-receptor of b cell antigen receptor complex (BCR) on b lymphocytes. Lower the threshold of downstream signaling pathway activation and trigger b-cell response to antigen (PubMed: 2463100, PubMed: 1373518, PubMed: 16672701). Activating the signaling pathway leads to the activation of phosphatidylinositol 3-kinase and mobilization of intracellular Ca(2+) storage (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701). Not needed in the early steps of bone marrow B cell differentiation (PubMed:9317126). Necessary for normal differentiation of B-1 cells (similarity). Normal B cell differentiation and proliferation are required to respond to antigen challenges (PubMed: 2463100, PubMed: 1373518). Requires normal levels of serum immunoglobulins, and high-affinity antibodies produced upon antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701). 发送反馈 历史记录
Field of research
Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody
Post-translational modifications
Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
Taplitumomab paptox
Description
Recombinant monoclonal antibody to CD19. Taplitumomab paptox is a mouse monoclonal antibody designed for the treatment of cancer The antibody itself, taplitumomab, is linked to the protein PAP, an antiviral from Phytolacca americana, a species of pokeweed. This is reflected by the 'paptox' in the drug's name.
Antibody Indication
Cancers
